Posted by Michael Wonder on 27 Jul 2017
Chiesi Group receives the European marketing authorisation for Trimbow (inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist)
24 July 2017 - Chiesi today announced that the European Commission has granted the marketing authorisation for Trimbow for the maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations).
As a result, Trimbow is now approved for use in the 31 European countries covered by the EMA, including the UK.
Trimbow is the first 3-in-1 combination inhaler containing an inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist containing beclometasone dipropionate (87 mcg), formoterol fumarate (5 mcg) and glycopyrronium (9 mcg), administered as a twice-daily fixed-dose in a pressurised metered-dose inhaler extra-fine formulation.
